CRISPR plants won't be regulated
Posted by btwatson on March 29, 2018 4:40 pm
Tags:
Categories:
Crispr Articles
Source: CRISPR plants won't be regulated

In a big win for the biotech industry, the US Department of Agriculture says it won’t regulate plants whose genomes have been altered using gene-editing technology.
Why it’s a field day: The decision means that we could see a boom in newfangled plants from firms like Monsanto, universities, and startups like Calyxt, whose oil-altered soybeans featured in our cover story late last year.
What changed? Under President Obama, the USDA laid out plans to regulate genetically edited plants for safety. But the Trump administration scuttled those rules. Now the USDA says these plants pose “no risk.”
Here’s the logic: The USDA says gene editing is just a (much) faster form of breeding. So long as a genetic alteration could have been bred into a plant, it won’t be regulated. That includes changes that create immunity to disease or natural resistance to crop chemicals, as well as edits to make seeds bigger and heavier. It doesn’t include transgenic plants (those with a gene from a distant species)—those will still be regulated.
Problems ahead: Trade in major crops is a global affair. Unless Europe and China agree with the US, exports of CRISPR plants could yet be blocked.
Image credit:
- ThiloBecker | Pixababy
Published at Thu, 29 Mar 2018 15:56:34 +0000
Crispr News
-
In Therapeutic Innovation, Digital Must Be Held to the Same Rigor ... - MedCity NewsMay 30, 2023
-
Modifying the Microbiome In Vivo, One Species or Gene at a Time - The ScientistMay 29, 2023
-
Resolving Discrepancies in Mouse and Human Autoimmunity Studies - The ScientistMay 29, 2023
-
Three technologies that could drive insurance's 'Blockbuster moment' - Insurance BusinessMay 29, 2023
-
CRISPR Unveils Plant Gene Potential - Mirage NewsMay 29, 2023
-
CRISPR studies identify many promising therapeutic targets for multiple myeloma - Medical XpressMay 29, 2023
-
Anti-CRISPR Protein Market Industries, Challenges And Global Demand Forecast Year 2030 - openPRMay 29, 2023
-
China's restrictions on flow of academic data sparks concerns among researchers globally - DevdiscourseMay 29, 2023
-
CRISPR Cas9 Market Analysis Report 2023 Along with Statistics ... - Digital JournalMay 29, 2023
-
Prediction: These 2 Stocks Could Double In the Next Year - The Motley FoolMay 28, 2023
-
CRISPR-modified pig sausages are now a thing, but would you eat one? - Interesting EngineeringMay 28, 2023
-
Genomics: Unraveling the Mysteries of the Genome with AI - CityLifeMay 27, 2023
-
3 No-Brainer Stocks to Buy for Under $100 Right Now - The Motley FoolMay 27, 2023
-
If I'd invested £1k in CRISPR Therapeutics shares on January 3, here's what I'd have now! - Motley Fool UKMay 27, 2023
-
If I’d invested £1k in CRISPR Therapeutics shares on January 3, here’s what I’d have now! - Yahoo Eurosport UKMay 27, 2023
- CRISPR rivals put patents aside to help in fight against Covid-19 – STAT
- CRISPR 2.0: Base Editing in the Groove – Genetic Engineering & Biotechnology News
- The Promises of CRISPR Genome Editing in Biomedicine – Labiotech.eu
- The Code Breaker and Crispr People — the ethics of editing humanity – Financial Times
- ERS Genomics Licenses CRISPR Patents to CRO ZeClinics – GenomeWeb
- The Dark Side of CRISPR – Scientific American
- ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement – BioSpace
- Scientists Use CRISPR To Create Model of AML Progression – AJMC.com Managed Markets Network
- DECODR app identifies DNA mutations from CRISPR gene therapies – European Pharmaceutical Review
- CRISPR/Cas technology as a promising weapon to combat viral infections – Wiley
- Neanderthal-like ‘mini-brains’ created in lab with CRISPR – Nature.com
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – Phys.org
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – EurekAlert
- New CRISPR tech targets human genome’s complex code: Programmable CRISPR/Cas9-based kinase offers insights into, control over regulatory histone proteins – Science Daily
- After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact – FierceBiotech
Leave a Reply
You must be logged in to post a comment.